Mein Warenkorb

CD206

CD206 Molekülinformation

Englischer NameMacrophage mannose receptor 1Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel2Target-AliasC-type lectin domain family 13 member D,CLEC13D,Macrophage mannose receptor 1-like protein 1,hMR,Macrophage mannose receptor 1,C-type lectin domain family 13 member D-like,CLEC13DL,MRC1L1,MRC1,Mannose Receptor C-Type 1,Mannose Receptor, C Type 1-Like 1,Human Mannose Receptor,MMR,Mannose Receptor, C Type 1,CD206 Antigen,BA541I19.1,CD206
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameMacrophage mannose receptor 1
Target-AliasC-type lectin domain family 13 member D,CLEC13D,Macrophage mannose receptor 1-like protein 1,hMR,Macrophage mannose receptor 1,C-type lectin domain family 13 member D-like,CLEC13DL,MRC1L1,MRC1,Mannose Receptor C-Type 1,Mannose Receptor, C Type 1-Like 1,Human Mannose Receptor,MMR,Mannose Receptor, C Type 1,CD206 Antigen,BA541I19.1,CD206
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphaseApproved

CD206 Molekülhintergrund

Mrc1 is a conserved checkpoint mediator protein that transduces the replication stress signal to the downstream effector kinase. Mrc1 and its vertebrate homologue Claspin serve as a mediator for replication stress checkpoint signaling, receiving the signal from Mec1/Rad3/ATR sensor kinase and transmitting it to the effector Rad53/Cds1/Chk1 kinase. The loss of mrc1 checkpoint activity results in the aberrant activation of late/dormant origins in the presence of hydroxyurea. Tumor-associated macrophages (TAMs) expressing the multi-ligand endocytic receptor mannose receptor (CD206/MRC1) contribute to tumor immunosuppression, angiogenesis, metastasis, and relapse.

CD206 Molekülalias

MMR,CD206,hMR,MRC1,CLEC13D,CLEC13DL,MRC1L1

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
68Ga-tilmanoceptPhase 3 ClinicalNavidea Biopharmaceuticals IncAtherosclerosis; Carcinoma, Endometrioid; Endometrial Neoplasms; Tuberculosis
Details
68GaNOTA-Anti-MMR-VHH2Phase 2 ClinicalUniversitair Ziekenhuis BrusselAtherosclerosis; Carcinoma, Non-Small-Cell Lung; Carotid Stenosis; Hodgkin Disease; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoidosis
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Technetium Tc 99m tilmanoceptNEO3-09ApprovedUniversity Of CaliforniaLymphoseek Kit, Lymphoseek, LymphoaimUnited StatesSolid tumours; Diagnostic agents; Breast Neoplasms; Melanoma; Carcinoma, Squamous Cell; Head and Neck NeoplasmsCardinal Health 414 Llc2013-03-13Anus Neoplasms; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Diagnostic agents; Endometrial Neoplasms; Head and Neck Neoplasms; HIV Infections; Liver Neoplasms; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Sarcoidosis; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns